Singular Genomics Systems (NASDAQ:OMIC) Issues Earnings Results, Beats Estimates By $1.33 EPS

Singular Genomics Systems (NASDAQ:OMIC) posted its earnings results on Tuesday. The company reported ($6.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.05) by $1.33, Zacks reports. The company had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.74 million. Singular Genomics Systems had a negative return on equity of 54.70% and a negative net margin of 3,237.89%.

Singular Genomics Systems Price Performance

NASDAQ OMIC traded down $0.13 during trading hours on Wednesday, hitting $22.84. 4,996 shares of the company were exchanged, compared to its average volume of 34,708. The company has a 50 day moving average of $14.66 and a two-hundred day moving average of $11.17. Singular Genomics Systems has a 52-week low of $5.34 and a 52-week high of $23.41. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.77 and a quick ratio of 8.04.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.